{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ABBV/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T19:02:46.151Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1099,"canonical_name":"AbbVie Inc.","cik":"0001551152","uei":null,"lei":null,"duns":null,"ticker":"ABBV"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":93,"sec":34,"fda":1},"count":100,"timeline":[{"ts":"2026-10-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07871513","excerpt":"[\"Upper Facial Lines\",\"Glabellar Lines\"]","importance":45},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"AbbVie","title":"Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07752979","excerpt":"[\"Obesity\",\"Overweight\"]","importance":45},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Participant Satisfaction After Jawline and Neck Treatment","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07794891","excerpt":"[\"Jawline and Neck Appearance\"]","importance":25},{"ts":"2026-10-07","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07862764","excerpt":"[\"Diffuse Large B-Cell Lymphoma\"]","importance":25},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07772492","excerpt":"[\"Severe Alopecia Areata\"]","importance":60},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07730554","excerpt":"[\"Forehead Lines\"]","importance":45},{"ts":"2026-10-05","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07821684","excerpt":"[\"Non-Squamous Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-10-05","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07697456","excerpt":"[\"Crohn's Disease\",\"Ulcerative Colitis\"]","importance":45},{"ts":"2026-10-05","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-10-05","url_slug":"/sec/cik-0001551152/8-k/0001551152-26-000030","accession_number":"0001551152-26-000030","importance":35},{"ts":"2026-10-05","kind":"clinical.trial","reporter":"AbbVie","title":"A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07856706","excerpt":"[\"Healthy Subjects\"]","importance":30},{"ts":"2026-10-02","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07581002","excerpt":"[\"Acute Myeloid Leukemia\"]","importance":60},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-10-02","url_slug":"/sec/cik-0001551152/4/0001997505-26-000010","accession_number":"0001997505-26-000010","importance":30},{"ts":"2026-09-30","kind":"clinical.trial","reporter":"AbbVie","title":"A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07599761","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-09-30","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07604558","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07744126","excerpt":"[\"Head and Neck Squamous Cell Carcinoma\"]","importance":45},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07673120","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07843693","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07607964","excerpt":"[\"Systemic Lupus Erythematosus\",\"Rheumatoid Arthritis\"]","importance":30},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07769502","excerpt":"[\"Pancreatobiliary Cancers\",\"Pancreatic Ductal Adenocarcinoma\"]","importance":45},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07832708","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-09-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07599670","excerpt":"[\"Alzheimer's Disease\"]","importance":45},{"ts":"2026-09-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07649954","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07756580","excerpt":"[\"Glabellar Lines\"]","importance":30},{"ts":"2026-09-08","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07807956","excerpt":"[\"Advanced Solid Tumors\",\"Non-Small Cell Lung Cancer\",\"Colorectal Cancer\",\"Pancreatic Ductal Adenocarcinoma\",\"Gastric Cancer\",\"Gastroesophageal Junction Adenocarcinoma\",\"Biliary Tract Cancer\",\"Head and Neck Squamous Cell Carcinoma\",\"Ovarian Cancer\"]","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-09-03","url_slug":"/sec/cik-0001551152/8-k/0001104659-26-104940","accession_number":"0001104659-26-104940","importance":35},{"ts":"2026-08-31","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07794878","excerpt":"[\"Nasolabial Folds\"]","importance":60},{"ts":"2026-08-28","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema","security_title":null,"status":"WITHDRAWN","accession_number":"NCT07604545","excerpt":"Company Decision","importance":80},{"ts":"2026-08-28","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07793422","excerpt":"[\"Amyloid Light Chain (AL) Amyloidosis\"]","importance":60},{"ts":"2026-08-18","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-08-18","url_slug":"/sec/cik-0001551152/8-k/0001104659-26-098367","accession_number":"0001104659-26-098367","importance":35},{"ts":"2026-08-18","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-08-18","url_slug":"/sec/cik-0001551152/4/0001762951-26-000006","accession_number":"0001762951-26-000006","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"144","title":"144 — AbbVie Inc. — 2026-08-14","url_slug":"/sec/cik-0001551152/144/0001950047-26-008158","accession_number":"0001950047-26-008158","importance":30},{"ts":"2026-08-14","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07587008","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-08-11","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07756645","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-08-10","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07680686","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"424B5","title":"424B5 — AbbVie Inc. — 2026-08-06","url_slug":"/sec/cik-0001551152/424b5/0001104659-26-092114","accession_number":"0001104659-26-092114","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-08-05","url_slug":"/sec/cik-0001551152/8-k/0001104659-26-091269","accession_number":"0001104659-26-091269","importance":35},{"ts":"2026-08-05","kind":"sec.filing","form_type":"FWP","title":"FWP — AbbVie Inc. — 2026-08-05","url_slug":"/sec/cik-0001551152/fwp/0001104659-26-090611","accession_number":"0001104659-26-090611","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"424B5","title":"424B5 — AbbVie Inc. — 2026-08-04","url_slug":"/sec/cik-0001551152/424b5/0001104659-26-090092","accession_number":"0001104659-26-090092","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"10-Q","title":"10-Q — AbbVie Inc. — 2026-08-03","url_slug":"/sec/cik-0001551152/10-q/0001551152-26-000026","accession_number":"0001551152-26-000026","importance":45},{"ts":"2026-08-03","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07736638","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-08-03","kind":"clinical.trial","reporter":"AbbVie","title":"Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07741838","excerpt":"[\"Atopic Dermatitis\"]","importance":25},{"ts":"2026-07-31","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-07-31","url_slug":"/sec/cik-0001551152/8-k/0001551152-26-000023","accession_number":"0001551152-26-000023","importance":35},{"ts":"2026-07-27","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07728188","excerpt":"[\"Relapsed or Refractory Multiple Myeloma\"]","importance":60},{"ts":"2026-07-20","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07600762","excerpt":"[\"Healthy Volunteer\"]","importance":30},{"ts":"2026-07-08","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07690215","excerpt":"[\"Migraine\"]","importance":25},{"ts":"2026-07-07","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07687602","excerpt":"[\"Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer\",\"Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer\",\"Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer\"]","importance":25},{"ts":"2026-07-06","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-07-06","url_slug":"/sec/cik-0001551152/8-k/0001551152-26-000021","accession_number":"0001551152-26-000021","importance":35},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — RAPP EDWARD J — 2026-07-02","url_slug":"/sec/cik-0001171780/4/0001171780-26-000012","accession_number":"0001171780-26-000012","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-07-02","url_slug":"/sec/cik-0001551152/4/0001997505-26-000008","accession_number":"0001997505-26-000008","importance":30},{"ts":"2026-06-29","kind":"clinical.trial","reporter":"AbbVie","title":"Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07673107","excerpt":"[\"Upper Limb Essential Tremor\"]","importance":45},{"ts":"2026-06-24","kind":"sec.filing","form_type":"11-K","title":"11-K — AbbVie Inc. — 2026-06-24","url_slug":"/sec/cik-0001551152/11-k/0001104659-26-077366","accession_number":"0001104659-26-077366","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SD","title":"SD — AbbVie Inc. — 2026-06-01","url_slug":"/sec/cik-0001551152/sd/0001104659-26-069017","accession_number":"0001104659-26-069017","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema","security_title":"PHASE2,PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07592273","excerpt":"[\"Diabetic Retinopathy\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06972446","excerpt":"[\"Rheumatoid Arthritis\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07155174","excerpt":"[\"Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06772623","excerpt":"[\"Non Small Cell Lung Carcinoma\"]","importance":45},{"ts":"2026-05-18","kind":"fda.recall","reporter":"AbbVie Inc.","title":"Class III","security_title":"PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product of France, NDC 11980-174-10.","excerpt":"Failed Stability Specifications","accession_number":"D-0551-2026","status":"Ongoing","product_type":"drug","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting","security_title":null,"status":"RECRUITING","accession_number":"NCT05094128","excerpt":"[\"Axial Spondylarthritis (r-axSpA)\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05652205","excerpt":"[\"Functional Constipation (FC)\",\"Chronic Idiopathic Constipation (CIC)\"]","importance":70},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05782907","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AbbVie","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06158841","excerpt":"[\"Multiple Myeloma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT04379050","excerpt":"[\"Parkinson's Disease (PD)\"]","importance":70},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07095452","excerpt":"[\"Multiple Myeloma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03844048","excerpt":"[\"Chronic Lymphocytic Leukemia\",\"Acute Myeloid Leukemia\",\"Multiple Myeloma\",\"Non-Hodgkin's Lymphoma\",\"Acute Lymphoblastic Leukemia\",\"Cancer\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05995353","excerpt":"[\"Crohn's Disease\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06734351","excerpt":"[\"Mid Face Volume Deficit\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05125302","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07005102","excerpt":"[\"Non-Squamous Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06100744","excerpt":"[\"Juvenile Psoriatic Arthritis\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06417775","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06822738","excerpt":"[\"Primary Open Angle Glaucoma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07071519","excerpt":"[\"Ulcerative Colitis\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06332534","excerpt":"[\"Crohn's Disease\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06696755","excerpt":"[\"Bipolar I Disorder\",\"Bipolar II Disorder\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06890338","excerpt":"[\"Epithelial Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Primary Peritoneal Cancer\",\"Neoadjuvant\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06158854","excerpt":"[\"Immunoglobulin Light Chain (AL) Amyloidosis\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07276997","excerpt":"[\"Major Depressive Disorder\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07387471","excerpt":"[\"Waldenstrom Macroglobulinemia\",\"Lymphoplasmacytic Lymphoma\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05005403","excerpt":"[\"Non-Small Cell Lung Cancer\",\"Head and Neck Squamous Cell Carcinoma\",\"Micro Satellite Stable Colorectal Cancer\",\"Gastric/Esophageal Cancer\",\"High-Grade Serous Ovarian Cancer\",\"Pancreatic Cancer\",\"Triple Negative Breast Cancer\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05650632","excerpt":"[\"Multiple Myeloma\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07291232","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Expanded Access to Telisotuzumab Vedotin","security_title":null,"status":"TEMPORARILY_NOT_AVAILABLE","accession_number":"NCT04830202","excerpt":"[\"Non-Small Cell Lung Cancer (NSCLC)\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis","security_title":null,"status":"RECRUITING","accession_number":"NCT07039110","excerpt":"[\"Plaque Psoriasis\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease","security_title":null,"status":"RECRUITING","accession_number":"NCT06965374","excerpt":"[\"Parkinson Disease\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AbbVie","title":"Expanded Access to Elezanumab","security_title":null,"status":"AVAILABLE","accession_number":"NCT04278235","excerpt":"[\"Acute Spinal Cord Injury (SCI)\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT04777357","excerpt":"[\"Depression\",\"Bipolar I Disorder\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06810505","excerpt":"[\"Chronic Migraine\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06241313","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06389136","excerpt":"[\"Atopic Dermatitis\"]","importance":60},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/8-k/0001104659-26-059484","accession_number":"0001104659-26-059484","importance":35},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001563579-26-000002","accession_number":"0001563579-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001706126-26-000002","accession_number":"0001706126-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001916665-26-000002","accession_number":"0001916665-26-000002","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — AbbVie Inc. — 2026-05-12","url_slug":"/sec/cik-0001551152/4/0001997505-26-000006","accession_number":"0001997505-26-000006","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06896916","excerpt":"[\"Multiple Myeloma\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06977724","excerpt":"[\"Dry Eye Syndrome\",\"Systemic Lupus Erythematosus\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis","security_title":null,"status":"RECRUITING","accession_number":"NCT06764706","excerpt":"[\"Ulcerative Colitis\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AbbVie","title":"Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06464692","excerpt":"[\"Colorectal Cancer\"]","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"10-Q","title":"10-Q — AbbVie Inc. — 2026-05-08","url_slug":"/sec/cik-0001551152/10-q/0001551152-26-000017","accession_number":"0001551152-26-000017","importance":45},{"ts":"2026-05-08","kind":"sec.insider.a","reporter":"AUSTIN ROXANNE S","title":"","shares":1118,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value","importance":15}]}